var data={"title":"Enoxaparin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Enoxaparin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6105?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=enoxaparin-drug-information\" class=\"drug drug_general\">see &quot;Enoxaparin: Drug information&quot;</a> and <a href=\"topic.htm?path=enoxaparin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Enoxaparin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708731\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Spinal/Epidural hematoma:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Epidural or spinal hematomas may occur in patients who are anticoagulated with LMWHs or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Factors that can increase the risk of developing epidural or spinal hematomas in these patients include use of indwelling epidural catheters; concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants; a history of traumatic or repeated epidural or spinal punctures; and a history of spinal deformity or spinal surgery. Optimal timing between the administration of enoxaparin and neuraxial procedures is not known.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165076\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Lovenox</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165077\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Lovenox;</li>\n      <li>Lovenox HP;</li>\n      <li>Lovenox With Preservative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052533\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anticoagulant</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Low Molecular Weight Heparin</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442390\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Enoxaparin has ~100 anti-factor Xa units/mg enoxaparin (World Health Organization First International Low Molecular Weight Heparin Reference Standard). In order to improve accurate measurement and avoid dilution of enoxaparin doses in neonates (including premature neonates weighing &lt;1,000 g), the following methods have reported at some centers: Dose rounding to the nearest whole mg (down or up, as appropriate) and administering with a &le;100 unit insulin syringe (see Preparation for Administration) (Bauman 2009a; Bauman 2009b; Goldsmith 2015); extra precaution should be taken to ensure accurate dose delivery.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis:</b> Limited data available: SubQ: 0.75 mg/kg/dose every 12 hours (Giglia 2013; Monagle 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thrombosis, treatment:</b> Limited data available<b>: Note:</b> Preliminary data from 213 pediatric patients evaluating 1,061 anti-factor Xa levels suggests that pediatric dose titration in patients &lt;2 years of age may be affected by assay methodology (Greene 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Initial:</i> SubQ: 1.5 mg/kg/dose every 12 hours (Monagle 2012); some data suggest that doses higher than those recommended in the <i>Chest</i> guidelines (Monagle 2012) are required in neonates (Malowany 2007; Malowany 2008; Sanchez de Toledo 2010); some centers have used the following initial doses:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Premature neonates: SubQ: 2 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Full-term neonates: SubQ: 1.7 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dosing adjustment:</i> Titrate dose to achieve a 4 to 6 hours postdose target anti-factor Xa level of 0.5 to 1 units/mL (Monagle 2012); duration of treatment based on thrombosis site, clinical response, and other identified risk factors; usual duration between 6 weeks and 3 months (Monagle 2012). A prospective study of 177 courses of enoxaparin in pediatric patients (146 treatment courses) reported considerable variation in maintenance dosage requirements (Dix 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Previous CHEST guidelines (Molinari 2011; Monagle 2001; Monagle 2008) suggested the following dosage adjustments to achieve the target anti-factor Xa range (Duplaga 2001).</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Enoxaparin Dosage Titration</caption>\n      <col></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Antifactor Xa</p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Dose Titration</p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Time to Repeat Antifactor Xa Level</p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">&lt;0.35 units/mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Increase dose by 25%</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4 h after next dose</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">0.35-0.49 units/mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Increase dose by 10%</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4 h after next dose</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">0.5-1 unit/mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Keep same dosage</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Next day, then 1 wk later, then monthly</p>\n            <p style=\"text-indent:0em;\">(4 h after dose)</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">1.1-1.5 units/mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Decrease dose by 20%</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Before next dose</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">1.6-2 units/mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Hold dose for 3 h</p>\n            <p style=\"text-indent:0em;\">and decrease dose by 30%</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Before next dose,</p>\n            <p style=\"text-indent:0em;\">then 4 h after next dose</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">&gt;2 units/mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Hold all doses until</p>\n            <p style=\"text-indent:0em;\">antifactor Xa is 0.5 units/mL,</p>\n            <p style=\"text-indent:0em;\">then decrease dose by 40%</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Before next dose and</p>\n            <p style=\"text-indent:0em;\">every 12 h until</p>\n            <p style=\"text-indent:0em;\">antifactor Xa &lt;0.5 units/mL</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052526\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=enoxaparin-drug-information\" class=\"drug drug_general\">see &quot;Enoxaparin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Enoxaparin has ~100 anti-factor Xa units/mg enoxaparin (World Health Organization First International Low Molecular Weight Heparin Reference Standard). In order to improve accurate measurement and avoid dilution of enoxaparin pediatric enoxaparin doses, the following methods have reported at some centers: Dose rounding to the nearest whole mg (down or up, as appropriate) and administering with &le;100 unit insulin syringe (see Preparation for Administration) (Bauman 2009a; Bauman 2009b); extra precaution should be taken to ensure accurate dose delivery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prophylaxis:</b> Limited data available (Giglia 2013; Monagle 2012):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 1 to &lt;2 months: SubQ: 0.75 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;2 months, Children, and Adolescents: SubQ: 0.5 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Thrombosis; treatment: Note:</b> Preliminary data from 213 pediatric patients evaluating 1,061 anti-factor Xa levels suggests that pediatric dose titration in patients &lt;2 years of age may be affected by assay methodology (Greene 2014); SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initial:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Chest</i>/AHA guidelines (Giglia 2013; Monagle 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants 1 to &lt;2 months: SubQ: 1.5 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants &ge;2 months, Children, and Adolescents: SubQ: 1 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Alternate dosing:</i> Some data suggest that initial doses higher than those recommended in the <i>Chest</i> guidelines (Monagle 2012) are required in pediatric patients (especially in young infants or critically ill) (Bauman 2009; Malowany 2007; Malowany 2008; Schoemer 2014). Some centers have used the following:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">1 to &lt;3 months: 1.8 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">3 to 12 months: 1.5 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">1 to 5 years: 1.2 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">6 to 18 years: 1.1 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dosing adjustment:</i> Titrate dose to achieve a 4 to 6 hours postdose target anti-factor Xa level of 0.5 to 1 units/mL (Monagle 2012); duration of treatment based on thrombosis site, clinical response, and other identified risk factors; usual duration between 6 weeks and 3 months (Monagle 2012). A prospective study of 177 courses of enoxaparin in pediatric patients (146 treatment courses) reported considerable variation in maintenance dosage requirements (Dix 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Previous CHEST guidelines (Molinari 2011; Monagle 2001; Monagle 2008) suggested the following dosage adjustments to achieve (Duplaga 2001).</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Enoxaparin Dosage Titration</caption>\n      <col></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Antifactor Xa</p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Dose Titration</p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Time to Repeat Antifactor Xa Level</p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">&lt;0.35 units/mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Increase dose by 25%</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4 h after next dose</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">0.35-0.49 units/mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Increase dose by 10%</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4 h after next dose</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">0.5-1 unit/mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Keep same dosage</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Next day, then 1 wk later, then monthly</p>\n            <p style=\"text-indent:0em;\">(4 h after dose)</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">1.1-1.5 units/mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Decrease dose by 20%</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Before next dose</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">1.6-2 units/mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Hold dose for 3 h</p>\n            <p style=\"text-indent:0em;\">and decrease dose by 30%</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Before next dose,</p>\n            <p style=\"text-indent:0em;\">then 4 h after next dose</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">&gt;2 units/mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Hold all doses until</p>\n            <p style=\"text-indent:0em;\">antifactor Xa is 0.5 units/mL,</p>\n            <p style=\"text-indent:0em;\">then decrease dose by 40%</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Before next dose and</p>\n            <p style=\"text-indent:0em;\">every 12 h until</p>\n            <p style=\"text-indent:0em;\">antifactor Xa &lt;0.5 units/mL</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> One mg of enoxaparin is equal to 100 units of anti-Xa activity (World Health Organization First International Low Molecular Weight Heparin Reference Standard). Weight-based doses (eg, 1 mg/kg) are commonly rounded to the nearest 10 mg; also see institution-specific rounding protocols if available. Most available prefilled syringes are graduated in 10 mg increments.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>DVT prophylaxis:</b> SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Obesity:</i> <b>Note:</b> In morbidly obese patients (BMI &ge;40 kg/m<sup>2</sup>), increasing the prophylactic dose by 30% may be appropriate for some indications (Nutescu 2009). For bariatric surgery, dose increases may be &gt;30% based on clinical trial data.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Abdominal surgery:</i> 40 mg once daily, with initial dose given 2 hours prior to surgery; continue until risk of DVT has diminished (usually 7 to 10 days).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hip replacement surgery:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Twice-daily dosing: 30 mg every 12 hours, with initial dose within 12 to 24 hours after surgery, and every 12 hours for at least 10 days or until risk of DVT has diminished or the patient is adequately anticoagulated on warfarin. The American College of Chest Physicians recommends initiation &ge;12 hours preoperatively <b>or</b> &ge;12 hours postoperatively; extended duration of up to 35 days suggested (Guyatt 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Once-daily dosing: 40 mg once daily, with initial dose within 9 to 15 hours before surgery, and daily for at least 10 days (or up to 35 days postoperatively) or until risk of DVT has diminished or the patient is adequately anticoagulated on warfarin. The American College of Chest Physicians recommends initiation &ge;12 hours preoperatively <b>or</b> &ge;12 hours postoperatively; extended duration of up to 35 days suggested (Guyatt 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Knee replacement surgery:</i> 30 mg every 12 hours, with initial dose within 12 to 24 hours after surgery, and every 12 hours for at least 10 days or until risk of DVT has diminished or the patient is adequately anticoagulated on warfarin. The American College of Chest Physicians recommends initiation &ge;12 hours preoperatively <b>or</b> &ge;12 hours postoperatively; extended duration of up to 35 days suggested (Guyatt 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Medical patients with severely restricted mobility during acute illness:</i> 40 mg once daily; continue until risk of DVT has diminished (usually 6 to 11 days)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>DVT treatment (acute):</b> SubQ: <b>Note:</b> Start warfarin on the first or second treatment day and continue enoxaparin until INR is &ge;2 for at least 24 hours (usually 5 to 7 days) (Guyatt 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Inpatient treatment (with or without pulmonary embolism):</i> 1 mg/kg/dose every 12 hours or 1.5 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Outpatient treatment (without pulmonary embolism):</i> 1 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Obesity:</i> Use actual body weight to calculate dose; dose capping not recommended; use of twice daily dosing preferred (Nutescu 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>ST-elevation MI (STEMI):</b> <i>Patients &lt;75 years of age:</i> Initial: 30 mg IV single bolus plus 1 mg/kg (maximum: 100 mg for the first 2 doses only) SubQ every 12 hours. The first SubQ dose should be administered with the IV bolus. Maintenance: After first 2 doses, administer 1 mg/kg SubQ every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Additional notes on STEMI treatment:</b> Therapy may be continued for up to 8 days or until revascularization. Unless contraindicated, all patients should receive aspirin (indefinitely) and clopidogrel (ACCF/AHA [O'Gara 2013]). In patients with STEMI receiving thrombolytics, initiate enoxaparin dosing between 15 minutes before and 30 minutes after fibrinolytic therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Unstable angina or non-ST-elevation MI (NSTEMI):</b> SubQ: 1 mg/kg every 12 hours in conjunction with oral aspirin therapy; continue for the duration of hospitalization (a minimum of at least 2 days) or up to 8 days (ACCF/AHA [Anderson 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Obesity:</i> Use actual body weight to calculate dose; dose capping not recommended (Nutescu 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Conversion:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conversion from IV unfractionated heparin (UFH) infusion to SubQ enoxaparin (Nutescu 2007):</i> Calculate specific dose for enoxaparin based on indication, discontinue UFH and begin enoxaparin within 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conversion from SubQ enoxaparin to IV UFH infusion (Nutescu 2007):</i> Discontinue enoxaparin, calculate specific dose for IV UFH infusion based on indication, omit heparin bolus/loading dose:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Converting from SubQ enoxaparin dosed every 12 hours: Start IV UFH infusion 10 to 11 hours after last dose of enoxaparin</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Converting from SubQ enoxaparin dosed every 24 hours: Start IV UFH infusion 22 to 23 hours after last dose of enoxaparin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;30 mL/minute: No specific adjustment recommended; monitor patients closely for bleeding</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute: <b>Note:</b> Monitor antifactor Xa activity closely.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">DVT prophylaxis in abdominal surgery, hip replacement, knee replacement, or in medical patients during acute illness: SubQ: 30 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">DVT treatment in conjunction with warfarin (in inpatient or outpatient treatment): SubQ: 1 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">STEMI: &lt;75 years: Initial: IV: 30 mg as a single dose with the first dose of the SubQ maintenance regimen administered at the same time as the IV bolus; Maintenance: SubQ: 1 mg/kg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Unstable angina, NSTEMI: SubQ: 1 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dialysis: Enoxaparin has not been FDA approved for use in dialysis patients. Its elimination is primarily via the renal route. Serious bleeding complications have been reported with use in patients who are dialysis dependent or have severe renal failure. LMWH administration at fixed doses without monitoring has greater unpredictable anticoagulant effects in patients with chronic kidney disease. If used, dosages should be reduced and anti-Xa levels frequently monitored, as accumulation may occur with repeated doses. Many clinicians would not use enoxaparin in this population especially without timely anti-Xa levels.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Supplemental dose is not necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis: Significant drug removal is unlikely based on physiochemical characteristics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165050\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lovenox: 300 mg/3 mL (3 mL) [contains benzyl alcohol, pork (porcine) protein]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 300 mg/3 mL (3 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous, as sodium [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lovenox: 30 mg/0.3 mL (0.3 mL); 40 mg/0.4 mL (0.4 mL); 60 mg/0.6 mL (0.6 mL); 80 mg/0.8 mL (0.8 mL); 100 mg/mL (1 mL); 120 mg/0.8 mL (0.8 mL); 150 mg/mL (1 mL) [contains pork (porcine) protein]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 30 mg/0.3 mL (0.3 mL); 40 mg/0.4 mL (0.4 mL); 60 mg/0.6 mL (0.6 mL); 80 mg/0.8 mL (0.8 mL); 100 mg/mL (1 mL); 120 mg/0.8 mL (0.8 mL); 150 mg/mL (1 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165035\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052538\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: For SubQ use only, do not administer IM or IV. Administer by deep SubQ injection; do not rub injection site after SubQ administration as bruising may occur. When administering 30 mg or 40 mg SubQ from a commercially prefilled syringe, do not expel the air bubble from the syringe prior to injection (in order to avoid loss of drug). IV administration is indicated as part of treatment of STEMI only; flush IV access with NS or D5W before and after enoxaparin IV bolus administration (to clear drug from port).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165069\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze. Do not store multiple-dose vials for &gt;28 days after first use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052537\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Prophylaxis for DVT following hip or knee replacement surgery, abdominal surgery, or in medical patients with severely restricted mobility during acute illness who are at risk for thromboembolic complications (ie, &gt;40 years of age, obese, general anesthesia &gt;30 minutes, malignancy, history of DVT, or pulmonary embolism); inpatient treatment of DVT (with or without pulmonary embolism); outpatient treatment of DVT without pulmonary embolism; prevention of ischemic complications with acute coronary syndromes, unstable angina, non-ST-elevation (NSTEMI) and ST-segment elevation myocardial infarction (STEMI) (All indications: FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165126\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lovenox may be confused with Lasix, Levaquin, Levemir, Lotronex, Protonix</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">National Patient Safety Goals:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Joint Commission (TJC) requires healthcare organizations that provide anticoagulant therapy to have a process in place to reduce the risk of anticoagulant-associated patient harm. Patients receiving anticoagulants should receive individualized care through a defined process that includes standardized ordering, dispensing, administration, monitoring and education. This does not apply to routine short-term use of anticoagulants for prevention of venous thromboembolism when the expectation is that the patient&rsquo;s laboratory values will remain within or close to normal values (NPSG.03.05.01).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165123\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As with all anticoagulants, bleeding is the major adverse effect of enoxaparin. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables. At the recommended doses, single injections of enoxaparin do not significantly influence platelet aggregation or affect global clotting time (ie, PT or aPTT).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Cardiovascular: Peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Confusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, ecchymoses, hemorrhage, major hemorrhage (includes cases of intracranial, retroperitoneal, or intraocular hemorrhage; incidence varies with indication/population), thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Bleeding at injection site, hematoma at injection site, pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Hematuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute posthemorrhagic anemia, atrial fibrillation, eosinophilia, epidural hematoma (spinal; after neuroaxial anesthesia or spinal puncture; risk may be increased with indwelling epidural catheter or concomitant use of other drugs affecting hemostasis), hepatic injury (hepatocellular and cholestatic), hyperkalemia, hyperlipidemia (very rare), hypersensitivity angiitis, hypersensitivity reaction, hypertriglyceridemia, osteoporosis (following long-term therapy), pneumonia, pulmonary edema, shock, skin necrosis, thrombocythemia, thrombosis in heparin-induced thrombocyptopenia, thrombosis (prosthetic value [in pregnant females] or associated with enoxaparin-induced thrombocytopenia; can cause limb ischemia or organ infarction)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165057\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Known hypersensitivity to enoxaparin (eg, pruritus, urticaria, anaphylactic/anaphylactoid reactions), heparin, pork products, or any component of the formulation (including benzyl alcohol in multiple-dose vials); history of immune mediated heparin-induced thrombocytopenia (HIT) in the past 100 days or in the presence of circulating antibodies; active major bleeding</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Use of multiple-dose vials in newborns or premature neonates; acute or subacute bacterial endocarditis; major blood clotting disorders; active gastric or duodenal ulcer; hemorrhagic cerebrovascular accident (except if there are systemic emboli); severe uncontrolled hypertension; diabetic or hemorrhagic retinopathy; other conditions or diseases involving an increased risk of hemorrhage; injuries to and operations on the brain, spinal cord, eyes, and ears; spinal/epidural anesthesia when repeated dosing of enoxaparin (1 mg/kg every 12 hours or 1.5 mg/kg daily) is required, due to increased risk of bleeding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165039\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: Monitor patient closely for signs or symptoms of bleeding. Certain patients are at increased risk of bleeding. Risk factors include bacterial endocarditis; congenital or acquired bleeding disorders; active ulcerative or angiodysplastic GI diseases; severe uncontrolled hypertension; hemorrhagic stroke; or use shortly after brain, spinal, or ophthalmic surgery; in patients treated concomitantly with platelet inhibitors; recent GI bleeding or ulceration; renal dysfunction and hemorrhage; thrombocytopenia or platelet defects or history of heparin-induced thrombocytopenia; severe liver disease; hypertensive or diabetic retinopathy; or in patients undergoing invasive procedures. Discontinue if bleeding occurs. Protamine may be considered as a partial reversal agent in overdose situations (consult Protamine monograph for dosing recommendations). To minimize risk of bleeding following PCI, achieve hemostasis at the puncture site after PCI. If a closure device is used, sheath can be removed immediately. If manual compression is used, remove sheath 6 hours after the last IV/SubQ dose of enoxaparin. Do not administer further doses until 6 to 8 hours after sheath removal; observe for signs of bleeding/hematoma formation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: Monitor for hyperkalemia; can cause hyperkalemia possibly by suppressing aldosterone production. Most commonly occurs in patients with risk factors for the development of hyperkalemia (eg, renal dysfunction, concomitant use of potassium-sparing diuretics or potassium supplements, hematoma in body tissues).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">.&bull; Thrombocytopenia: Thrombocytopenia can occur. Cases of enoxaparin-induced thrombocytopenia with thrombosis, some complicated by organ infarction, limb ischemia, or death, have been observed; monitor platelet count closely. Use with extreme caution or avoid in patients with history of HIT (Warkentin 2001); use is contraindicated in patients with a history of immune-mediated HIT within the past 100 days or in the presence of circulating antibodies. In patients with a history of HIT, use only if &gt;100 days have elapsed since the prior HIT episode and no circulating antibodies are present (HIT may still occur in these patients; assess risk vs benefit and use only after non-heparin alternative treatments are considered). Discontinue therapy and consider alternative treatment if platelets are &lt;100,000/mm<sup>3</sup> and/or thrombosis develops. Use caution in patients with congenital or drug-induced thrombocytopenia or platelet defects.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prosthetic heart valves: Cannot be recommended for long-term thromboprophylaxis in patients with prosthetic heart valves (especially pregnant women) due to insufficient evidence.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal failure; dosage adjustment needed if CrCl &lt;30 mL/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; delayed elimination may occur. Dosage alteration/adjustment may be required (eg, omission of IV bolus in acute STEMI in patients &ge;75 years of age).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Low weight patients: Risk of bleeding may be increased in women &lt;45 kg and in men &lt;57 kg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obesity: Safety and efficacy of prophylactic dosing of enoxaparin has not been established in patients who are obese (&gt;30 kg/m<sup>2</sup>) nor is there a consensus regarding dosage adjustments; monitor closely for signs/symptoms of thromboembolism. Anti-Xa levels are increased to appropriate levels when enoxaparin is dosed on actual body weight in obese patients weighing up to 144 kg (Sanderink 2002). Monitoring of anti-Xa levels 4 hours after the dose may be warranted. The American College of Chest Physicians Practice Guidelines suggest consulting with a pharmacist regarding dosing in bariatric surgery patients and other obese patients who may require higher doses of LMWH (ACCP [Gould 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: In patients receiving bridging anticoagulation with therapeutic dose enoxaparin, the American College of Chest Physicians suggests that the last preoperative dose of enoxaparin be administered ~24 hours prior to surgery (ACCP [Douketis 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol and should not be used in pregnant women. In neonates, large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;); the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Do <b>not </b>administer intramuscularly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conversion to other products: Not to be used interchangeably (unit for unit) with heparin or any other low molecular weight heparins.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuraxial anesthesia:<b> [US Boxed Warning]: Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include use of indwelling epidural catheters; concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants; a history of traumatic or repeated epidural or spinal punctures; and a history of spinal deformity or spinal surgery. Optimal timing between the administration of enoxaparin and neuraxial procedures is not known. Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary. <b>Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis. </b></b>Delay placement or removal of catheter for at least 12 hours after administration of low-dose enoxaparin (eg, 30 to 60 mg/day) and at least 24 hours after high-dose enoxaparin (eg, 0.75 to 1 mg/kg twice daily or 1.5 mg/kg once daily); risk of neuraxial hematoma may still exist since antifactor Xa levels are still detectable at these time points. Patients receiving twice daily high-dose enoxaparin should have the second dose withheld to allow a longer time period prior to catheter placement or removal. Upon removal of catheter, consider withholding enoxaparin for at least 4 hours. <b>Consider doubling these times in patients with creatinine clearance &lt;30 mL/minute. If anticoagulation is administered during or immediately following diagnostic lumbar puncture, epidural anesthesia/analgesia, or spinal anesthesia/analgesia monitor frequently for signs and symptoms of neurological impairment (midline back pain, sensory and motor deficits, bowel or bladder dysfunction).</b> If spinal hematoma is suspected, diagnose and treat immediately; spinal cord decompression may be considered although it may not prevent or reverse neurological sequelae.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299264\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165044\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13270&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">5-Aminosalicylic Acid Derivatives: May enhance the adverse/toxic effect of Heparins (Low Molecular Weight). Specifically, the risk for bleeding/bruising may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antithrombin: May enhance the anticoagulant effect of Heparins (Low Molecular Weight).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canagliflozin: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Canagliflozin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Anticoagulants may enhance the anticoagulant effect of Desirudin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another.  See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of estrogens against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<b> Exceptions: </b>Tibolone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Factor X (Human): Anticoagulants (Inhibitors of Factor Xa) may diminish the therapeutic effect of Factor X (Human). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: Heparins (Low Molecular Weight) may increase the serum concentration of Palifermin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the anticoagulant effect of Heparins (Low Molecular Weight).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Salts: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Potassium Salts. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.  Management: Monitor serum potassium concentrations closely. The spironolactone Canadian product monograph lists its combination with heparin or low molecular weight heparins as contraindicated.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins: May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165046\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165060\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Low molecular weight heparin (LMWH) does not cross the placenta; increased risks of fetal bleeding or teratogenic effects have not been reported (Bates 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">LMWH is recommended over unfractionated heparin for the treatment of acute venous thromboembolism (VTE) in pregnant women. LMWH is also recommended over unfractionated heparin for VTE prophylaxis in pregnant women with certain risk factors (eg, homozygous factor V Leiden, antiphospholipid antibody syndrome with &ge;3 previous pregnancy losses). Prophylaxis is not routinely recommended for women undergoing assisted reproduction therapy; however, LMWH therapy is recommended for women who develop severe ovarian hyperstimulation syndrome. LMWH should be discontinued at least 24 hours prior to induction of labor or a planned cesarean delivery. For women undergoing cesarean section and who have additional risk factors for developing VTE, the prophylactic use of LMWH may be considered (Bates 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">LMWH may also be used in women with mechanical heart valves (consult current guidelines for details) (Bates 2012; Nishimura 2014). Women who require long-term anticoagulation with warfarin and who are considering pregnancy, LMWH substitution should be done prior to conception when possible. When choosing therapy, fetal outcomes (ie, pregnancy loss, malformations), maternal outcomes (ie, VTE, hemorrhage), burden of therapy, and maternal preference should be considered (Bates 2012). Monitoring antifactor Xa levels is recommended (Bates 2012; Nishimura 2014).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Multiple-dose vials contain benzyl alcohol (avoid in pregnant women due to association with gasping syndrome in premature infants); use of preservative-free formulations is recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052532\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with platelets, stool occult blood tests, serum creatinine and potassium; antifactor Xa activity in select patients (eg, neonates, infants, children, obese patients, and patients with significant renal impairment, active bleeding, or abnormal coagulation parameters); <b>Note</b>: Routine monitoring of PT and APTT is not warranted since PT and APTT are relatively insensitive measures of low molecular weight heparin activity; consider monitoring bone density in infants and children with long-term use</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052536\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Antifactor Xa: <b>Note:</b> The following are suggested peak values of antifactor Xa. Once daily dosing in pediatric patients is not feasible due to faster enoxaparin clearance and lower drug exposure in pediatric patients compared to adults (O&rsquo;Brien 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Therapeutic:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates and Children: 0.5 to 1.0 units/mL, measured 4 to 6 hours after SubQ administration <b>or</b> 0.5 to 0.8 units/mL, measured 2 to 6 hours after SubQ administration (Monagle 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Once-daily dosing: &gt;1 anti-Xa units/mL (Garcia 2012); the manufacturer recommends a range of 1 to 2 anti-Xa units/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Twice-daily dosing: 0.6 to 1 anti-Xa units/mL (Garcia 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prophylactic:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: Prevention of central venous access device related DVT: 0.1 to 0.3 units/mL, measured 4 to 6 hours after SubQ administration (Monagle 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 0.2 to 0.4 units/mL (Nutescu 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165038\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Standard heparin consists of components with molecular weights ranging from 4000 to 30,000 daltons with a mean of 16,000 daltons. Heparin acts as an anticoagulant by enhancing the inhibition rate of clotting proteases by antithrombin III impairing normal hemostasis and inhibition of factor Xa. Low molecular weight heparins have a small effect on the activated partial thromboplastin time and strongly inhibit factor Xa. Enoxaparin is derived from porcine heparin that undergoes benzylation followed by alkaline depolymerization. The average molecular weight of enoxaparin is 4500 daltons which is distributed as (&le;20%) 2000 daltons (&ge;68%) 2000 to 8000 daltons, and (&le;18%) &gt;8000 daltons. Enoxaparin has a higher ratio of antifactor Xa to antifactor IIa activity than unfractionated heparin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165056\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Peak effect: SubQ: Antifactor Xa and antithrombin (antifactor IIa): 3 to 5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: 40 mg dose: Antifactor Xa activity: ~12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: 4.3 L (based on antifactor Xa activity)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Does not bind to heparin binding proteins </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic, via desulfation and depolymerization to lower molecular weight molecules with very low biological activity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Adults: SubQ: ~100%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination, plasma: 2 to 4 times longer than standard heparin, independent of dose; based on anti-Xa activity: 4.5 to 7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (40% of dose as active and inactive fragments; 10% as active fragments; 8% to 20% of antifactor Xa activity is recovered within 24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: Decreased by 30% in patients with CrCl &lt;30 mL/minute </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165059\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Enoxaparin Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/3 mL (3 mL): $84.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Enoxaparin Sodium Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg/0.3 mL (0.3 mL): $5.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/0.4 mL (0.4 mL): $7.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg/0.6 mL (0.6 mL): $10.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg/0.8 mL (0.8 mL): $14.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (1 mL): $18.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg/0.8 mL (0.8 mL): $21.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg/mL (1 mL): $27.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Lovenox Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/3 mL (3 mL): $297.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Lovenox Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg/0.3 mL (0.3 mL): $29.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/0.4 mL (0.4 mL): $39.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg/0.6 mL (0.6 mL): $59.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg/0.8 mL (0.8 mL): $79.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (1 mL): $99.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg/0.8 mL (0.8 mL): $119.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg/mL (1 mL): $149.07</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165062\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bnoxaparin (PH);</li>\n      <li>Clenox (CO, PE);</li>\n      <li>Clexane (AE, AR, AU, BB, BE, BF, BG, BH, BJ, BM, BS, CH, CI, CL, CN, CO, CR, CU, CY, CZ, DE, DO, EC, EE, EG, ES, ET, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, HU, IE, IL, IN, IT, JM, JO, JP, KE, KR, KW, LK, LR, LT, LU, LV, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NZ, PA, PE, PH, PK, PL, PR, PY, QA, RO, RU, SA, SC, SD, SG, SI, SK, SL, SN, SV, TH, TN, TR, TT, TW, TZ, UG, UY, VE, VN, ZM, ZW);</li>\n      <li>Clexane Forte (AU, IL, SG);</li>\n      <li>Cutenox (LK);</li>\n      <li>Dilutol (EC, VN);</li>\n      <li>Enoclex (PH);</li>\n      <li>Kleksan (UA);</li>\n      <li>Klexane (DK, FI, IS, NO, SE);</li>\n      <li>Lomoh-40 (PH, ZW);</li>\n      <li>Lomoh-60 (PH);</li>\n      <li>Lovenox (AT, FR, ID, LB, PT);</li>\n      <li>Microparin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Olxarin (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson JL, Adams CD, Antman EM, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(23):e663-e828.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/23630129/pubmed\" target=\"_blank\" id=\"23630129\">23630129</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bates SM, Greer IA, Middeldorp S, et al. &ldquo;VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):e691-736.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/22315276/pubmed\" target=\"_blank\" id=\"22315276\">22315276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauman ME, Belletrutti MJ, Bajzar L, et al, &quot;Evaluation of Enoxaparin Dosing Requirements in Infants and Children. Better Dosing to Achieve Therapeutic Levels,&quot; <i>Thromb Haemost</i>, 2009b, 101(1):86-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/19132193/pubmed\" target=\"_blank\" id=\"19132193\">19132193</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauman ME, Black KL, Bauman ML, &quot;Novel Uses of Insulin Syringes to Reduce Dosing Errors: A Retrospective Chart Review of Enoxaparin Whole Milligram Dosing,&quot; <i>Thromb Res</i>, 2009a, 123(6):845-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/19038418/pubmed\" target=\"_blank\" id=\"19038418\">19038418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bontadelli J, Moeller A, Schmugge M, et al, &quot;Enoxaparin Therapy for Arterial Thrombosis in Infants With Congenital Heart Disease,&quot; <i>Intensive Care Med</i>, 2007, 33(11):1978-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/17554520/pubmed\" target=\"_blank\" id=\"17554520\">17554520</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    deVeber G, Chan A, Monagle P, et al, &ldquo;Anticoagulation Therapy in Pediatric Patients With Sinovenous Thrombosis: A Cohort Study,&rdquo; <i>Arch Neurol</i>, 1998, 55(12):1533-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/9865797 /pubmed\" target=\"_blank\" id=\"9865797 \">9865797 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dix D, Andrew M, Marzinotto V, et al, &ldquo;The Use of Low Molecular Weight Heparin in Pediatric Patients: A Prospective Cohort Study,&rdquo; <i>J Pediatr</i>, 2000, 136(4):439-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/10753240/pubmed\" target=\"_blank\" id=\"10753240\">10753240</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2 Suppl):e326S-350S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/22315266/pubmed\" target=\"_blank\" id=\"22315266\">22315266</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dunaway KK, Gal P, and Ransom JL, &quot;Use of Enoxaparin in a Preterm Infant,&quot; <i>Ann Pharmacother</i>, 2000, 34(12):1410-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/11144698/pubmed\" target=\"_blank\" id=\"11144698\">11144698</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. <i>Pharmacotherapy</i>. 2001;21(2):218-234.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/11213859/pubmed\" target=\"_blank\" id=\"11213859\">11213859</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia DA, Baglin TP, Weitz JI, et al, &ldquo;Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):24-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/22315264/pubmed\" target=\"_blank\" id=\"22315264\">22315264</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giglia TM, Massicotte MP, Tweddell JS, et al. Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2013;128(24):2622-2703.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/24226806/pubmed\" target=\"_blank\" id=\"24226806\">24226806</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldsmith R, Chan AK, Paes BA, Bhatt MD, Thrombosis and Hemostasis in Newborns (THiN) Group. Feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates. <i>J Perinatol</i>. 2015;35(10):852-854<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/22315264/pubmed\" target=\"_blank\" id=\"22315264\">22315264</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in Nonorthopedic Surgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2):S227-S277.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/22315263/pubmed\" target=\"_blank\" id=\"22315263\">22315263</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greene LA, Law C, Jung M, et al. Lack of anti-factor Xa assay standardization results in significant low molecular weight heparin (enoxaparin) dose variation in neonates and children. <i>J Thromb Haemost</i>. 2014;12(9):1554-1557.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/24943261/pubmed\" target=\"_blank\" id=\"24943261\">24943261</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hirsh J, Guyatt G, Albers GW, et al, &ldquo;Executive Summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),&rdquo; <i>Chest</i>, 2008, 133(6 Suppl):71-109.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/18574259/pubmed\" target=\"_blank\" id=\"18574259\">18574259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hirsh J, Warkentin TE, Shaughnessy SG, et al, &ldquo;Heparin and Low-Molecular-Weight Heparin: Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety,&rdquo; <i>Chest</i>, 2001, 119:64S-94S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/11157643/pubmed\" target=\"_blank\" id=\"11157643\">11157643</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearon C, Kahn SR, Agnelli G, et al, &quot;Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),&quot; <i>Chest</i>, 2008, 33(6 Suppl):454-545.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/18574272/pubmed\" target=\"_blank\" id=\"18574272\">18574272</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    King SB 3rd, Smith SC Jr, Hirshfeld JW JR, et al, &ldquo;2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee,&rdquo; <i>Circulation</i>, 2008, 117(2):261-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/18079354/pubmed\" target=\"_blank\" id=\"18079354\">18079354</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lovenox injection (enoxaparin) [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; October 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malowany JI, Knoppert DC, Chan AK, et al, &quot;Enoxaparin Use in the Neonatal Intensive Care Unit: Experience Over 8 Years,&quot; <i>Pharmacotherapy</i>, 2007, 27(9):1263-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/17723080/pubmed\" target=\"_blank\" id=\"17723080\">17723080</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malowany JI, Monagle P, Knoppert DC, et al, &quot;Enoxaparin for Neonatal Thrombosis: A Call for a Higher Dose for Neonates,&quot; <i>Thromb Res</i>, 2008, 122(6):826-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/18207492/pubmed\" target=\"_blank\" id=\"18207492\">18207492</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martineau P and Tawil N, &ldquo;Low-Molecular-Weight Heparins in the Treatment of Deep-Vein Thrombosis,&rdquo; <i>Ann Pharmacother</i>, 1998, 32(5):588-98, 601.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/9606481/pubmed\" target=\"_blank\" id=\"9606481\">9606481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Massicotte P, Adams M, Marzinotto V, et al, &ldquo;Low-Molecular-Weight Heparin in Pediatric Patients With Thrombotic Disease: A Dose Finding Study,&rdquo; <i>J Pediatr</i>, 1996, 128(3):313-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/8774496 /pubmed\" target=\"_blank\" id=\"8774496 \">8774496 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Michaels LA, Gurian M, Hegyi T, et al, &quot;Low Molecular Weight Heparin in the Treatment of Venous and Arterial Thromboses in the Premature Infant,&quot; <i>Pediatrics</i>, 2004, 114(3):703-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/15342842/pubmed\" target=\"_blank\" id=\"15342842\">15342842</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Molinari AC, Saracco P, Cecinati V, et al. Venous thrombosis in children: an emerging issue. <i>Blood Coagul Fibrinolysis</i>. 2011;22(5):351-361.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/21681083/pubmed\" target=\"_blank\" id=\"21681083\">21681083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Monagle P, Chalmers E, Chan A, et al, &quot;Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),&quot; <i>Chest</i>, 2008, 133(6 Suppl):887S-968S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/18574281/pubmed\" target=\"_blank\" id=\"18574281\">18574281</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Monagle P, Chan A, Goldenberg NA, et al, &quot;Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition),&quot; <i>Chest</i>, 2012, 141(2 Suppl):e737-801.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/22315277/pubmed\" target=\"_blank\" id=\"22315277\">22315277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Monagle P, Michelson AD, Bovill E, et al, &ldquo;Antithrombotic Therapy in Children,&rdquo; <i>Chest</i>, 2001, 119:344S-70S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/11157659/pubmed\" target=\"_blank\" id=\"11157659\">11157659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nutescu EA and Dager W, &ldquo;Heparin, Low Molecular Weight Heparin, and Fondaparinux,&rdquo; <i>Managing Anticoagulation Patients in the Hospital</i>, Gulseth M ed, American Society of Health-System Pharmacists&reg;, Bethesda, MD: 2007, 181.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nutescu EA, Spinler SA, Wittkowsky A, et al, &quot;Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings,&quot; <i>Ann Pharmacother</i>, 2009, 43(6):1064-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/19458109/pubmed\" target=\"_blank\" id=\"19458109\">19458109</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Brien SH, Lee H, and Ritchey AK, &quot;Once-Daily Enoxaparin in Pediatric Thromboembolism: A Dose Finding and Pharmacodynamics/Pharmacokinetics Study,&quot; <i>J Thromb Haemost</i>, 2007, 5(9):1985-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/17596139/pubmed\" target=\"_blank\" id=\"17596139\">17596139</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.<i> Circulation</i>. 2013;127(4):e362-425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanchez de Toledo J, Gunawardena S, Munoz R, et al, &quot;Do Neonates, Infants and Young Children Need a Higher Dose of Enoxaparin in the Cardiac Intensive Care Unit?&quot; <i>Cardiol Young</i>, 2010, 20(2):138-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/20199704/pubmed\" target=\"_blank\" id=\"20199704\">20199704</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanderink GJ, Le Liboux A, Jariwala N, et al, &ldquo;The Pharmacokinetic and Pharmacodynamics of Enoxaparin in Obese Volunteers,&rdquo; <i>Clin Pharmacol Ther</i>, 2002, 72(3):308-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/12235452/pubmed\" target=\"_blank\" id=\"12235452\">12235452</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schloemer NJ, Abu-Sultaneh S, Hanson SJ, Yan K, Hoffmann RG, Punzalan RC, Havens PL. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children. <i>Pediatr Crit Care Med</i>. 2014;15(7):e294-299.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/24901803/pubmed\" target=\"_blank\" id=\"24901803\">24901803</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warkentin TE and Kelton JG, &ldquo;Temporal Aspects of Heparin-Induced Thrombocytopenia,&rdquo; <i>N Engl J Med</i>, 2001, 344(17):1286-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/enoxaparin-pediatric-drug-information/abstract-text/11320387/pubmed\" target=\"_blank\" id=\"11320387\">11320387</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13270 Version 155.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708731\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F165076\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F165077\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1052533\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442390\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1052526\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F165050\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F165035\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1052538\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F165069\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1052537\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F165126\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F165123\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F165057\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F165039\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299264\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F165044\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F165046\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F165060\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1052532\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1052536\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F165038\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F165056\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F165059\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F165062\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13270|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=enoxaparin-drug-information\" class=\"drug drug_general\">Enoxaparin: Drug information</a></li><li><a href=\"topic.htm?path=enoxaparin-patient-drug-information\" class=\"drug drug_patient\">Enoxaparin: Patient drug information</a></li></ul></div></div>","javascript":null}